A61P 13/00
Drugs for disorders of the urinary system
A61P13/00 (Drugs for disorders of the urinary system) appears on 24,810 US grants and 36,690 published applications in this corpus.
Search patents in A61P- Granted patents
- 24,810
- Published applications
- 36,690
- Assignees
- 7,634
- Inventors
- 50,763
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 5 | 0 |
| 1978 | 12 | 0 |
| 1979 | 7 | 0 |
| 1980 | 9 | 0 |
| 1981 | 18 | 0 |
| 1982 | 14 | 0 |
| 1983 | 10 | 0 |
| 1984 | 15 | 0 |
| 1985 | 15 | 0 |
| 1986 | 20 | 0 |
| 1987 | 22 | 0 |
| 1988 | 28 | 0 |
| 1989 | 41 | 0 |
| 1990 | 62 | 0 |
| 1991 | 72 | 0 |
| 1992 | 68 | 0 |
| 1993 | 98 | 0 |
| 1994 | 81 | 0 |
| 1995 | 152 | 0 |
| 1996 | 164 | 0 |
| 1997 | 231 | 0 |
| 1998 | 300 | 0 |
| 1999 | 302 | 0 |
| 2000 | 354 | 0 |
| 2001 | 411 | 121 |
| 2002 | 504 | 695 |
| 2003 | 507 | 1167 |
| 2004 | 437 | 1532 |
| 2005 | 462 | 1567 |
| 2006 | 675 | 1624 |
| 2007 | 680 | 1673 |
| 2008 | 771 | 1959 |
| 2009 | 916 | 2211 |
| 2010 | 1266 | 2572 |
| 2011 | 1274 | 2205 |
| 2012 | 1468 | 2105 |
| 2013 | 1642 | 1832 |
| 2014 | 1621 | 1889 |
| 2015 | 1408 | 1724 |
| 2016 | 1251 | 1695 |
| 2017 | 1298 | 1641 |
| 2018 | 1134 | 1459 |
| 2019 | 1073 | 1347 |
| 2020 | 903 | 1157 |
| 2021 | 791 | 977 |
| 2022 | 593 | 916 |
| 2023 | 465 | 820 |
| 2024 | 468 | 726 |
| 2025 | 446 | 682 |
| 2026 | 243 | 394 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61P 13/12Drugs for disorders of the urinary system: of the kidneys16,097
- A61P 13/02Drugs for disorders of the urinary system: of urine or of the5,246
- A61P 13/08Drugs for disorders of the urinary system: of the prostate4,815
- A61P 13/10Drugs for disorders of the urinary system: of the bladder3,526
- A61P 13/04Drugs for disorders of the urinary system: for urolithiasis265
- A61P 13/06Anti-spasmodics209
Recent patents
- Composition containing a yeast for preventing simple and/or recurring cystitis6 Oct 2026US 12,751,984 B2Lesaffre Et Compagnie
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene6 Oct 2026US 12,752,019 B2Precision BioSciences, Inc.
- PHD inhibitor compounds, compositions, and use6 Oct 2026US 12,753,161 B2Akebia Therapeutics, Inc.
- TGFbeta1-binding immunoglobulins and use thereof6 Oct 2026US 12,753,226 B2Scholar Rock, Inc.
- Medicament containing enteropeptidase inhibitor as active ingredient, and method for preventing and or treating polycystic kidney disease containing administering the same8 Oct 2026US 2026/0306441 A1National University Corporation Hokkaido University
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Sik inhibitors to treat chronic kidney disease8 Oct 2026US 2026/0306463 A1The General Hospital Corporation
- Functional protective agent for organ or tissue8 Oct 2026US 2026/0306488 A1Jellice Co., Ltd.
- Methods and pharmaceutical compositions comprising d1-like dopamine receptor agonist for the treatment of autosomal dominant polycystic kidney disease8 Oct 2026US 2026/0306504 A1Centre Hospitalier Universitaire De Rouen
Most cited
By later US patents
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005
- Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions616US 6,569,463 B2Lipocine Inc. · 2003
- Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity604US 6,602,684 B1GlycArt Biotechnology AG · 2003
- Human antibodies that bind human TNF.alpha.451US 6,090,382 ABASF SE · 2000